ENvue’s UroShield Secures UK NHS Reimbursement
ENvue Medical’s UroShield Kit is added to the NHS Drug Tariff Part IX, enabling nationwide reimbursement and triggering early commercial orders in the UK.
Market Access
CMS Reopens National TAVR Coverage Review at Edwards’ Request
CMS has accepted Edwards Lifesciences’ request to reopen the national coverage determination for TAVR, launching a review that could expand access to asymptomatic patients and ease procedural barriers by late 2026.
ICER Backs Wegovy, Zepbound Value in Obesity but Flags Access Crunch
The Institute for Clinical and Economic Review (ICER) has delivered a strong clinical and economic endorsement of today’s leading obesity drugs, while simultaneously warning that U.S. payers are unprepared for the scale of demand these therapies are likely to generate. In a final evidence report released Tuesday, ICER concluded that Novo Nordisk’s semaglutide (Wegovy, injectable … Read more
EU Greenlights Landmark Pharma Package, Overhauling Drug Rules for the First Time in 20 Years
The EU has finalized a sweeping Pharma Package deal, preserving eight years of data protection, adding new antibiotic incentives and giving member states new powers to secure medicine supply.
ICER Advances Two High-Stakes Assessments: Cytisinicline Cleared, IgAN Therapies Under Review
ICER released two notable updates this week: a final evidence report supporting cytisinicline’s role in smoking cessation and a draft review evaluating sibeprenlimab, atacicept and delayed-release budesonide for IgA nephropathy.
UK Cuts VPAG Newer-Medicine Rate to 14.5% for 2026
The UK has set the 2026 VPAG newer-medicine rebate at 14.5%, down sharply from 22.9% in 2025, reflecting slower NHS uptake and easing budget pressure. With an added 1% contribution, companies will pay 15.5% next year as talks begin to redesign the scheme for 2029 and beyond.
China’s 2026 NRDL Drives Major Breakthroughs in Drug Access
China’s latest National Reimbursement Drug List (NRDL), set to take effect on January 1, 2026, is reshaping competitive dynamics across oncology, rare disease, and chronic metabolic care, as a wave of domestic and multinational companies secured new listings or renewed coverage for some of their highest-priority medicines. The update coincides with the release of the … Read more
Seven NRDL Wins Position Innovent for Volume-Driven Growth in 2025
Innovent Biologics closed out the year with one of its most consequential access wins to date, securing National Reimbursement Drug List (NRDL) inclusion for seven innovative medicines spanning oncology, immunology, metabolism, and rare disease. The breadth of updates underscores how the company’s maturing R&D engine, lifecycle management strategy, and pricing discipline are converging to generate … Read more
G-BA Clears 2026 Launch of Biologic Substitution Rules
Germany has cleared the way for pharmacy-level substitution of prescribed biologics with lower-cost biosimilars starting in 2026.
White House and London Clinch Drug-Pricing Deal With 25% UK Price Lift
The U.S. and U.K. have reached an agreement in principle that lifts U.K. net prices for new innovative medicines by 25 percent, caps VPAG repayments at 15 percent from 2026 onward, and exempts U.K.-origin pharmaceutical and medical goods from Section 232 tariffs.